Halozyme Therapeutics Inc (HALO)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$61.00

Buy

$65.00

arrow-up$0.31 (+0.50%)

Prices updated at 13 Dec 2025, 00:40 EST

Prices minimum 15 mins delay

Prices in USD

Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Jeffrey W. Henderson

CEO

Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B.

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

350

Head office

12390 El Camino Real

San Diego

United States

92130

+1 858 794-8889

ir@halozyme.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Nicole LaBrosse Senior Vice President, Chief Financial Officer and Principal Accounting Officer	0.57m
Ms. Cortney Caudill Senior Vice President and Chief Operating Officer	-
Mr. James Lang Director	-
Mr. Jeffrey W. Henderson Chairman of the Board	0.14m
Dr. Helen I. Torley, M.R.C.P.,MB.Ch.B. Director, President and Chief Executive Officer	0.96m
Mr. Matthew L. Posard Independent Director	0.06m
Ms. Barbara G. Duncan Independent Director	0.09m
Ms. Bernadette M. Connaughton Independent Director	0.07m
Mr. Mark Snyder Senior Vice President, General Counsel, Chief Compliance Officer and Secretary	0.58m
Ms. Moni Miyashita Independent Director	0.06m
Dr. Mahesh Krishnan, M.B.A. Independent Director	0.04m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	12,860,199
Vanguard Group Inc	12,245,602
BlackRock Fund Advisors	8,042,211
State Street Corp	5,019,207
Vanguard Investments Australia Ltd	3,904,509

Director dealings

Date chevron-l-regular chevron-r-regular	Action
29 Nov 2024	-
29 Nov 2024	-
15 Oct 2024	-
15 Oct 2024	-
16 Oct 2024	-
16 Oct 2024	-
15 Oct 2024	-
15 Oct 2024	-
15 Oct 2024	-
15 Oct 2024	-
16 Oct 2024	-
08 Oct 2024	-
09 Oct 2024	-
08 Oct 2024	-
09 Oct 2024	-
09 Oct 2024	-
09 Oct 2024	-
09 Oct 2024	-
08 Oct 2024	-
08 Oct 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.